Table 6.
BMC evaluation during PRME administration period
| Regions | SC (g) | OVX (g) | OVX + PRME (g) | OVX + Std (g) |
|---|---|---|---|---|
| Arms | 0.87 ± 0.12 | 0.33 ± 0.17 | 0.47 ± 0.35 | 0.58 ± 0.34 |
| Legs | 1.87 ± 0.31 | 2.1 ± 0.66 | 1.98 ± 0.82 | 1.76 ± 0.84 |
| Trunk | 2.9 ± 0.52 | 1.93 ± 0.38 | 2.32 ± 0.51 | 2.78 ± 0.54 |
| Total | 8.03 ± 0.35 | 6.97 ± 0.21 | 7.37 ± 0.46 | 7.6 ± 0.39 |
| TBLH | 5.63 ± 0.21 | 4.4 ± 0.53 | 4.8 ± 0.68 | 5.12 ± 0.54 |
Where; OVX ovariectomized rat, SC Sham control, OVX + PRME variectomized rat + Pterospermum rubiginosum methanolic extract, OVX + std ovariectomized rat + alendronic acid; bone mineral content—BMC, g grams